Clinical evaluation of a powder of quality elk velvet
antler for the treatment of osteoarthrosis in dogs
Maxim Moreau, Jacques Dupuis, Norbert H Bonneau, Manon Lécuyer
Abstract — A powder of quality elk velvet antler (QEVA) was evaluated on client-owned dogs with
osteoarthrosis (OA) in a clinical, double-blind, and placebo-controlled study. Thirteen dogs received
a placebo for 30 days and then QEVA for 60 days. Twenty-five other dogs received QEVA for 60 days.
Gait analysis measured with a force plate, clinical signs assessed by an orthopedic surgeon,
performances in daily life activities and vitality assessed by the owners, and complete blood analyses
were obtained at days 0, after 30 days of placebo and/or 60 days of QEVA. On placebo, the 13 dogs
did not show significant improvement (P
0.05); however, their gait, their performances in daily
life activities, and their vitality were significantly improved on QEVA, based on changes in values
exceeding those observed when placebo was administered. The 25 dogs on QEVA for 60 days showed
similar improvements. No clinical changes were revealed on blood analyses. Administration of QEVA
was effective in alleviating the condition in arthritic dogs.
Résumé — Évaluation clinique de l'utilisation d'une poudre faite à partir de bois de velours
de cerf de bonne qualité dans le traitement d'ostéoarthrose chez le chien.
Une poudre faite à
partir de bois de velours de cerf de qualité a été évaluée chez des chiens ayant de l'ostéoarthrose lors
d'une étude clinique à double insu. Trente chiens ont reçu un placebo pendant 30 jours et, par la suite,
de la poudre de bois de velours pendant 60 jours. Vingt-cinq autres chiens ont reçu de la poudre de
bois de velours pendant 60 jours. L'analyse de la démarche a été faite à l'aide d'une plate-forme. Les
signes cliniques ont été évalués par un chirurgien orthopédiste. Les performances et l'entrain dans
les activités quotidiennes ont été évalués par les propriétaires. Des analyses sanguines complètes ont
été faites au jour 0, après 30 jours de placebo ou 60 jours de poudre de bois de velours. Les 13 chiens
ayant reçu le placebo n'ont pas montré d'amélioration significative (P
0,05); cependant, leur
démarche, leurs performances lors d'activités quotidiennes et leur vitalité se sont améliorées consi-
dérablement après qu'ils eurent reçu de la poudre de bois de velours, cette conclusion repose sur les
écarts de valeurs plus important que ceux observés chez les chiens ayant reçu le placebo. Les
25 chiens qui ont reçu la poudre de bois de velours pendant 60 jours ont connu des améliorations
similaires. Les analyses sanguines n'ont révélé aucun changement clinique. L'administration de la
poudre de bois de velours s'est avérée efficace pour améliorer l'état des chiens arthritiques.
(Traduit par Docteure Andrée Lesage)
Can Vet J 2004;45:133–139
used clinically in East Asia for thousands of years in the
Osteoarthrosis (OA) is a painful musculoskeletal treatment of various diseases and as a tonic (9). This
condition in dogs, often being secondary to struc-
traditional Chinese medicine is a nutritional supplement
tural abnormalities, such as hip or elbow dysplasia or
made from the inner core of elk antler in the velvet stage
ligament injury. Disturbance in the normal homeostasis
of growth. Observations from in vivo studies demon-
of joint tissue between degradation and synthesis is
strated an antiinflammatory eff
f ect of a peptide (pilose
involved in this degenerative process, visually character-
antler peptide) isolated from velvet antler in a rodent
ized by articular surface erosion, bone sclerosis, and
model of inflammation (9,10). T
hese studies, combined
osteophyte production, leading to pain, joint stiffness,
with the knowledge that chondroitin sulfate is found in
and muscular atrophy (1–4).
velvet antler,r suggested that this material could be useful
Research has led to the development of a broad range
in the treatment of OA (11,12).
of pharmaceutical approaches to alleviate clinical signs
by acting on the degenerative process, the associated
the health benefits of a powder of quality elk velvet
inflammatory process, or both (5–8). Elk velvet antler is
antler,r referred here to QEVA
V , by administering it at the
a well-known Chinese materia medica, which has been
manufacturer's recommended dosage to a pool of client-
owned dogs afflicted with OA.
The companion animal research group, Faculté de médecine
Materials and methods
St-Hyacinthe Quebec J2S 7C6.
Address all correspondence and reprint requests to Dr.r Maxim
Dogs weighing more than 20 kg and older than 18 mo
Moreau; e-mail: [email protected]
were included in the study.
y All dogs had radiographic
A in 1 or more joints. The OA
This study was generously supported by Qeva V
have been determined to be the cause of the clinical
Can Vet J Volume 45, February 2004
signs, including an algetic gait, by a complete orthopedic
group their dog had been assigned, and about the contents
examination performed by an orthopedic surgeon (JD or
of the capsules administered to their dog. Surgeons were
NHB). The algetic gait reported by the owner had to be
unaware of the GRF, had no communication with the
chronic and stable. Dogs with rupture of the cranial
owners, and did not know about the assigned group. Dogs
cruciate ligament were admitted, if the rupture had been
meeting all enrolment criteria were randomly assigned to
surgically repaired more than 1 y previously. Dogs were
1 of these 2 experimental groups.
also included if a complete cranial cruciate ligament
rupture had been diagnosed more than 1 y previously and
had not been surgically corrected at that time and if they
Dogs weighing between 20 and 39.9 kg, 40 and 59.9 kg,
were without evidence of gross instability (drawer
and 60 and 79.9 kg received 2, 3, and 4 capsules of placebo,
movement) at the time they were presented for the study.
respectively, PO, q12h for 30 d, starting on day 0. Following
Concurrent treatment for OA was not permitted during
this, dogs weighing between 20 and 39.9 kg, 40 and 59.9 kg,
the course of the study. If dogs had previously received
and 60 and 79.9 kg received 2, 3, and 4 capsules of QEVA,
treatment, the following predetermined withdrawal
respectively, PO, q12h for 60 d, from days 31 to 90. Each
periods were observed: 2 wk for oral nonsteroidal
capsule of placebo contained a mixture of flour (unbleached
antiinflammatory drugs, 3 wk for oral corticosteroids,
r anic romano bean), powder (arrowroot, roaster
and 12 wk for injectable corticosteroids. A 4-week with-
drawal period was required following oral administration
contained 280 mg of a pure powder of elk (Cornu cervi
of glucosamine, chondroitin sulphate, or both, while a
velvet antler (Cartiplex; Qeva Velvet Products, Calgary,
24-week withdrawal period was required following
injectable polysulfated polysaccharide. Pregnant bitches
and dogs suffering from neurologic or other musculo-
30 d had changed. The following 60 d were used to evalu-
skeletal lesions were excluded. Dogs that had undergone
ate the effects of QEVA.
orthopedic surgery within the past year were also
excluded. Recruitment was done through telephone calls
Quality elk velvet antler group
to clients selected from the medical files of the Veterinary
Dogs between 20 and 39.9 kg, 40 and 59.9 kg, and 60 to
Teaching Hospital of the Université de Montréal and
79.9 kg received 2, 3, and 4 capsules of QEVA, respectively,
advertisements in newspapers. Dog owners involved in
PO, q12h for 60 d, starting on day 0. Each capsule contained
the study were required to sign a consent form.
280 mg of QEVA.
returned to the V
T aching Hospital for 2nd and
The experimental protocol was approved by the Animal
3rd visits on days 30 and 90, respectively.
Care and Use Committee of the Université de Montréal and
dogs included in the QEVA
A group returned to the
was in accordance with the Guidelines of the Canadian
T aching Hospital for a 2nd visit on day 60.
Council for Animal Care (13). On day 0, owners and dogs
At the time of these visits, owners were asked again to
attended the Veterinary Teaching Hospital for the first
visit. Owners were asked to score performances in daily
an assessment of increasing vitality by using a dichoto-
life activities by using an owner's assessment form
mous key (yes or no) and to report side eff
f ects related to
(Appendix 1). Scores for each activity were then summated
treatment. Dogs were weighed, their gait was analyzed,
to generate a score for activity performances. Dogs were
and an orthopedic examination was carried out. Owners
weighed and their gait was analyzed by using ground
were asked to return any unused medication, so that it
reaction forces (GRF) obtained by a biomechanical force
could be verified that it had been given as prescribed.
plate (Model OR6-6; Advanced Mechanical Technology,
Watertown, USA). Visual examination of the gait and
Equipment and gait analysis protocol
complete orthopedic and neurologic examinations were then
Ground reaction forces were obtained by using a
carried out by 1 of 2 surgeons. After the examination, the
permanently mounted biomechanical force plate that had
surgeon attributed scores for the clinical signs of the most
been levelled with the floor in a 10-m runway and
severely affected joint by using a surgeon's assessment form
interfaced with a dedicated computer and software
(Appendix 2). In both assessment forms, higher scores
V tforce; Sharon Software, Michigan, USA) specially
meant severe clinical signs. Radiographic evaluations of
designed for the acquisition, numerical conversion, and
elbows, hips, and stifles were performed under routine
storage of values. Tr
T ot was maintained at a constant
sedation in all dogs; if necessary, additional radiographs
velocity between 1.9 and 2.2 m/s. A
A chronometer was
were obtained for specific joints. A radiographic score of
used to ensure that the dogs crossed the 10-m runway in
OA was attributed to each joint only on day 0 (Appendix 3).
between 4.5 and 5.2 s. The objective gait analysis
Blood samples were obtained by jugular venipuncture for
hematological and biochemical analyses to detect any pre-
f ected joint, responsible for most of the clinical signs
study abnormalities and to obtain basal values. Owners were
and algetic gait, as determined by the orthopedic
informed that dogs selected for the study would receive
examination. In the vertical axis, GRF obtained for the
either a placebo or an OA medication over 2 or 3 visits.
evaluated limb were the peak (maximal force) and
Orthopedic examinations were successively conducted
impulse (force integrated over time). In the craniocaudal
during a period of 6 mo and included between clinical cases,
axis, the peak and impulse for the braking (cranial)
thus confounding observation on day 0 and at re-evaluations.
and propulsive (caudal) portions of this GRF were also
obtained. At least 5 valid trials with a stance time
Can Vet J Volume 45, February 2004
Table 1. Mean and standard error (s
) of the mean changes from pretreat-
ment for ground reaction forces and surgeon and owners' assessments in
13 dogs with osteoarthrosis after 30 d of treatment with placebo and then
60 d of treatment with a powder of quality elk velvet antler (QEVA)
Changes from pretreatment
Ground reaction forces 30 d of placebo 60 d of QEVA
Vertical peak 0.047, s
= 1.500 4.102, s
= 1.000a impulse 0.094, s
= 0.214 0.091, s
= 0.163Craniocaudal braking portion peak 0.151, s
= 0.202 0.870, s
impulse 0.009, s
= 0.017 0.052, s
= 0.057Propulsive portion peak 0.412, s
= 0.330 0.313, s
= 0.356 impulse 0.056, s
= 0.039 0.020, s
Changes from pretreatment
Assessments (scores) 30 d of placebo 60 d of QEVA
Surgeon clinical signs 0.00, s
= 0.43 0.15, s
= 0.49 visual appreciation 4.30, s
= 5.70 6.38, s
= 5.56Owner activity performances 1.00, s
= 0.63 6.92, s
= 1.45aaPretreatment values significantly different from posttreatment values with changes significantly different from those of placebo (P
determined by the software of 0.650 s were retained;
in the placebo-treated group by using a chi-square test.
invalid trials were rejected, as previously described (14).
) values less than 0.05 were considered
Normalized values in percentage of body weight for the
evaluated limb were averaged and analyzed from the first
5 valid trials. Vertical GRF peak was designated as the
primary outcome measurement of the study.
Age, weight, GRF, duration of clinical signs, radio-
graphic findings, and assessment scores were not
Forty-five (45) dogs afflicted with OA were included
f erent between groups, and the weights
in the study; 5 (11%), 22 (49%), 13 (28%), 1 (2%), and
of dogs obtained at each visit did not diff
f er significantly.
4 (9%) dogs with clinical and radiographic evidence of
Table 1 presents the changes from pretreatment observed
OA of the elbow, hip, stifle, shoulder and tarsus, respec-
in the placebo-QEVA
A group for GRF and assessments
tively. There were 33 purebred and 12 mixed breed dogs
after 30 d of treatment with placebo and then after 60 d
with ages ranging from 21 to 148 mo, with an average
of treatment with QEVA.
of 82 mo. Their weight ranged from 25 to 71 kg, with
an average of 42 kg.
assessments obtained for the 13 dogs in this group were
not significantly diff
f erent from those obtained before
treatment (day 0). Only 1 owner reported an increased
The Wilcoxon rank-sum test was used to evaluate the
homogeneity between groups. Posttreatment GRF and
of treatment with QEVA
V , the vertical GRF peak and the
assessment scores were compared with pretreatment
craniocaudal GRF peak for the braking portion for these
(day 0 or 30) scores by using the Wilcoxon signed-
rank test for paired data. Changes from pretreatment
for QEVA-treated dogs were calculated and compared
pretreatment scores significantly exceeded the changes
with similar changes for placebo-treated dogs by using
the Wilcoxon signed-rank test for paired data in the
placebo-QEVA group and the Wilcoxon rank-sum test
as indicated by a significant reduction, compared with
in the QEVA group. An improvement was defined as an
pre-treatment (day 30) in activity performance scores.
increase in GRF and a decrease in assessment scores.
Changes in activity performances significantly exceeded
The proportion of dogs with an increased vitality in the
those observed after these dogs received the placebo. In
V -treated group was compared with that of dogs
these 13 dogs, 9 owners reported an increasing vitality
Can Vet J Volume 45, February 2004
Table 2. Mean and standard error (s
) a of the mean changes from pretreatment for ground reaction forces
and surgeon and owners' assessments in dogs with osteoarthrosis after 60 d of treatment with a powder of
quality elk velvet antler (QEVA)
Changes from pretreatment
Ground reaction forces group (25)
group (38) subset (19)
Vertical force peak 2.381, s
= 0.590b 2.514, s
impulse 0.160, s
= 0.109 0.130, s
Craniocaudal force braking portion peak 0.529, s
= 0.251a 0.726, s
impulse 0.042, s
= 0.023b 0.051, s
Propulsive portion peak 0.060, s
= 0.193 0.124, s
impulse 0.024, s
= 0.022 0.033, s
Changes from pretreatment
Assessments (scores) group (25)
group (38) subset (19)
Surgeon clinical signs 0.68, s
= 0.37 0.21, s
visual appreciation 5.40, s
= 3.40 5.68, s
Owner activity performances 8.00, s
= 0.96a 8.63, s
aPretreatment values significantly different from posttreatment values with changes significantly different from those of placebo (P
0.05)bPretreatment values significantly different from posttreatment values (P
after 60 d of treatment with QEVA. This proportion (9/13)
was significantly higher compared with the proportion
group (18/25), pooled group (27/38), and hips subset (14/19),
observed after treatment with placebo (1/13).
but not in the stifles subset (6/12).
Table 2 presents the changes from pretreatment scores
for GRF and assessments after 60 d of treatment with
Side effects and sample exclusion
QEVA. Ground reaction forces and assessments were
recorded for the QEVA group of dogs and the dogs
monitored revealed no evidence of abnormalities of any
pooled from the placebo-QEVA and QEVA groups.
clinical relevance following administration of placebo or
Subsets for stifles and hips were created from this pool
V , and the owners reported no side eff
of 38 dogs to provide distinction in treatment effects
to their administration.
according to evaluated joints.
Seven dogs did not complete the study. In the placebo-
The vertical GRF peak observed after 60 d of treatment
A group, a pregnant bitch was withdrawn from the
with QEVA was significantly improved in the QEVA group,
y and another dog was withdrawn when the owner
pooled group, and in the hips and stifles subsets compared
decided to stop the study for reasons unrelated to the
with the pretreatment peak. Also, the craniocaudal GRF peak
experimental context. Also in this group, a 4-year-
and impulse for the braking portion were significantly
Great Pyrenees died after 30 d of QEVA
improved in the QEVA group, pooled group, and hips subset,
history of anorexia, lethargy
history of anorexia, lethar , and vomiting. On necropsy
, and vomiting. On necropsy
but not in the stifles subset. Except for the braking impulse
macroscopic examination revealed bilateral reduction in
in the pooled group, these changes significantly exceeded
size of the adrenal glands, which was confirmed by
those observed in the 13 dogs that received the placebo only.
microscopic examination. The final diagnosis was
According to owners' assessment, activity performances
chronic adrenal atrophy with degeneration and fibrosis
were significantly improved in dogs in the QEVA group, the
of the cortical region of the adrenal glands. In the QEVA
pooled group, and in the hips and stifles subsets, as indicated
group, a 10-year-
r old dog died after 38 d of QEVA
by a significant reduction in activity performances scores
compared with pretreatment (day 0) evaluations. Changes
from the surface of the right atrium and on the spleen. A
from pretreatment scores significantly exceeded the changes
final diagnosis of hemangiosarcoma of the right atrium
observed after the 13 dogs had received the placebo.
r old American bulldog developed
Assessments by the surgeon did not note significant
diarrhea after 2 d of QEVA
V . Based on owner information
differences from pretreatment scores. Eighteen, 27, 14,
and a medical history that this dog had previously
and 6 owners reported an increased vitality in the QEVA
demonstrated enteric problems with susceptibility to
group, pooled group, hips, and stifle subsets, respectively.
diarrhea associated with dietary changes, the owner
Compared with placebo (1/13), proportions of dogs with an
decided to withdraw his dog. Following a history of
Can Vet J Volume 45, February 2004
diarrhea and 40 d of QEVA, a 5-year-old bobtail died;
According to the owners' 'assessment, QEVA
its alkaline phosphatase prior to treatment was 531 U/L.
dogs demonstrated a beneficial response. At home,
Macroscopic examination revealed pulmonary congestion
arthritic dogs improved their physical performances,
and bilateral atrophy of the adrenal glands with a thin
accompanied by an increasing vitality.
cortical region. The liver was pale and friable. Bilateral
this appreciation, QEVA
A prevented or decreased the
atrophy of the cortical region of the adrenal glands with
deleterious effect of inactivity by providing vigor
mild lymphoid adrenalitis and vacuolar hepatopathy was
and favoring resumption of normal activities of daily
diagnosed. Finally, to avoid concomitant medication, the
life. Although no improvements were observed by the
investigators decided to withdraw a dog with a prior
V -treated dogs, visual appreciation
history of dermatological problems that required corti-
showed a decrease in score, while an increase in score
costeroid therapy during the course of the study.
was observed in placebo-treated dogs. Whether adjust-
ment in dose to provide a greater amount of QEVA
longer therapy might result in better improvement in
orthopedic examination needs further investigation.
Kinetic measurement of musculoskeletal limb function
A were described by using subsets
has been used in different ways to comparatively evaluate
to determine if a distinction existed between treatment
response to different treatments (15–17), impact of acute
synovitis (14), and surgical procedures (18). The biome-
joints. Results showed that a diff
f erence in response was
chanical force plate used in this study allows a noninva-
in fact present, with less improvement of GRF and
sive and objective quantification of the forces transmitted
vitality for dogs with arthritic stifles. Based on a previous
through a single limb to the ground. Concerning the limb
study on the marked effect of a nonsteroidal antiinflam-
with the most severely affected joint, the vertical and
matory drug on canine stifles, we speculated that this
craniocaudal GRF were obtained pretreatment to create
f er in etiopathogenesis, resulting possibly
an arthritic pattern that could be compared with the GRF
in a more pronounced inflammatory process associated
obtained posttreatment. The difference in GRF and in
with an injury to the cruciate ligament (15). A
assessments scores pre- and posttreatment represents the
to this speculation, the distinction in improvement could
effect of the treatment on the arthritic condition.
be related to the major inflammatory process associated
The efficacy of QEVA was evaluated objectively on
with cruciate disease and a less eff
f ective treatment with
dogs afflicted with OA by using a description of the gait.
A when pronounced inflammation is present. This
Although some GRF were obtained and analyzed, vertical
hypothesis was suggested by clinical observations, thus
GRF peak was chosen as a primary outcome measure of
it is limited in scope.
improvement, thus limiting the probability of getting an
There was no alteration in the biochemical and hemato-
improvement by chance alone. The GRF generated by the
musculoskeletal system and transmitted to the affected
3 deaths occurred. One of these deaths was related to a
limb were increased in QEVA-treated dogs, thereby
hemangiosarcoma; however, the 2 other cases showed
indicating an improvement. The vertical GRF peak reflects
similar postmortem lesions on microscopic examination:
the maximal weight bearing of the dog. Dogs treated with
atrophy of the cortical region of the adrenal glands. In one
QEVA applied a greater magnitude of weight on their
case, the degree of fibrosis observed suggested that the
worst limb during the stance phase. This improvement in
lesions were secondary to cortical necrosis. The severe
weight support may be related to an increase in muscular
hyperkalemia, obtained from postmortem analysis of
strength, a decrease in joint inflammation, or both. Indeed,
vitreous humor, supports the hypothesis of cardiogenic and
when muscular mass is able to adequately support limb
circulatory shock following adrenocortical insufficiency. In
loading, reduction in joint loading occurs. This myotropic
the other case, pulmonary and hepatic congestion suggested
effect can improve the arthritic gait by limiting the delete-
that death was caused by a vascular shock.
rious action of joint loading. Also, when the inflammatory
process in a joint is reduced, relief of pain related to
dy with 2 deaths with similar lesions, safety of
hyperalgesia occurs (19). This reduction in joint inflam-
this medication needed to be demonstrated further: Oral
mation can improve the arthritic gait by limiting the pain
related to biochemical mediators released from OA
cartilage, synovial membrane, and nerve fibers from the
surrounding articular tissues (20–22).
rodents (Cartiplex; Qeva Ve
V lvet Products, personal
The craniocaudal GRF generated during the stance
phase is divided into a braking and a propulsive por-
gross pathologic examination revealed no evidence of
tion. At the beginning of the stance phase, dogs decrease
their momentum; then they propel their body forward
of a rapid withdrawal of exogenous corticosteroids (24).
before lifting the limb from the ground to increase
their momentum (23). Dogs treated with QEVA were
corticosteroid therapies had never been used previously.
able to increase their maximal braking force and also
Organochlorine compounds, such as dichloro-diphenyl-
increase their total applied braking force. Based on
trichloroethane (DDT) and its derivatives, can produce
gait analysis, QEVA-treated dogs improved their
weight bearing, accepted an algetic portion of the
In order to determine the presence of noxious substances
stance phase, and executed the stride in a comfortable
in the QEVA capsules, investigators submitted the medica-
tion used in both of these dogs to an independent
Can Vet J Volume 45, February 2004
laboratory (Bodycote-Envirolab, Ste-Foy, Quebec) to
screen for 20 potential pesticides, including DDT and its
1. Martel-Pelletier J, Alaaeddine N, Pelletier JP.
P Cytokines and their
derivatives. Results obtained by gas chromatographic
role in the pathophysiology of osteoarthritis. Front Biosci 1999;
analyses showed no detectable traces of any pesticides.
Also, in order to document the adrenocortical function of
2. Martinez SA. Congenital conditions that lead to osteoarthritis in
QEVA-treated dogs, adrenal response following synthetic
the dog. Vet Clin North Am Small Anim Pract 1997;27:735–758.
3. Martinez SA, Coronado GS. Acquired conditions that lead to
adrenocorticotropin hormone (ACTH) injection was
osteoarthritis in the dog. Ve
V t Clin North Am Small Anim Pract
evaluated. Five dogs receiving QEVA during 16, 20, 22,
60, and 60 d were tested: Basal and stimulated cortisol
4. Johnston SA. Joint anatomy,
y and pathobiology.
concentrations were all within the normal range values,
Clin North Am Small Anim Pract 1997;27:699–723.
indicating a normal adrenal function. Based on these
5. Fernandes JC, Caron JP,
P Martel-Pelletier J, et al. Eff
f ects of tenidap
findings and with the fact that in both cases the pathologist
model. Suppression of metalloprotease and interleukin-1 activity.
could not rule out shock following naturally occurring
Arthritis Rheum 1997;40:284–294.
adrenocortical insufficiency, these deaths were determined
6. Johnson KA, Hulse DA, Hart RC, Kochevar D, Chu Q. Effects of an
to be unrelated to QEVA treatment. However, a laboratory
orally administered mixture of chondroitin sulfate, glucosamine hydrochloride and manganese ascorbate on synovial fluid chondroitin
work-up must be considered for QEVA-treated dogs
sulfate 3B3 and 7D4 epitope in a canine cruciate ligament transection
showing clinical signs similar to those reported here.
model of osteoarthritis. Osteoarthritis Cartilage 2001;9:14–21.
Elk are farmed to produce velvet antler teas, extracts,
7. Blot L, Marcelis A, Devogelaer JP,
P Manicourt DH. Effects of
or capsules of raw material for human and animal health
diclofenac, aceclofenac and meloxicam on the metabolism of
benefits. It is well established that velvet antler contains
proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol 2000;131:1413–1421.
collagen as a major protein; a small amount of glycosami-
8. Pelletier JP, Lajeunesse D, Jovanovic DV, et al. Carprofen simul-
noglycans, primarily as chondroitin sulfate (11,12);
taneously reduces progression of morphological changes in
a peptide of 68 amino acids called pilose antler peptide
cartilage and subchondral bone in experimental dog osteoarthritis.
(9,10), and an alcohol extract known as pantocrin or
J Rheumatol 2000;27:2893–2902.
9. Zhang ZQ, Zhang Y,
W ng BX, Zhou HO, Wa
rantarin (27,28). Chondroitin sulfate possesses documented
Purification and partial characterization of anti-inflammatory
antiarthritic effects and is the major glycosaminoglycans
peptide from pilose antler of Cervus nippon Temminck
present in velvet antler (29). We consider that its presence
Xue Bao 1992;27:321–324.
in QEVA was not associated with the beneficial effects
10. Zhang ZQ, Wang Y, Zhang H, Zhang W, Zhang Y, Wang BX. Anti-
observed in this study, since, in another study performed
f ects of pilose antler peptide. Zhongguo Ya
Xue Bao 1994;15:282–284.
by our group (15), administration of a nutraceutical
11. Sunwoo HH, Sim LY
T Hudson RJ, Sim JS.
providing chondroitin sulfate in greater amounts than
Glycosaminoglycans from growing antlers of wapiti (Cervus
the raw material administered in this study failed to
). Can J Anim Sci 1997;77:715–721.
demonstrate significant gait improvement. The beneficial
12. Sunwoo HH, Nakano T, Hudson RJ, Sim JS. Isolation, characteriza-
effects of QEVA could be associated, in part with the
tion and localization of glycosaminoglycans in growing antlers of wapiti (Cervus elaphus
). Comp Biochem Physiol B Biochem Mol
antiinflammatory action of pilose antler peptide and with
the action of pantocrin. Therapeutic claims reported for
13. Guidelines for the Canadian Council for Animal Care. Canadian
pantocrin include increased work capacity, increased
Council for Animal Care, 315–350 Albert Street, Ottawa, Ontario.
recovery from training, decreased skeletal muscle fatigue
F Kincaid SA, Baird DK, Kammermann JR, V
V rtical ground reaction force distribution during
(adaptogenic properties), and a stimulating effect (30). To
experimentally induced acute synovitis in dogs. Am J Ve
reinforce our hypothesis of a myotropic effect provided
by QEVA, clinical signs were analyzed separately to
15. Moreau M, Dupuis J, Bonneau NH, Desnoyers M. Clinical evalu-
evaluate the effect on muscular mass in the QEVA and
ation of a nutraceutical, carprofen and meloxicam for the treatment
pooled groups. Although the cumulative score for clinical
of dogs with osteoarthritis. Vet Rec 2003;152:323–329.
signs did not show significant improvement, palpation of
f icacy in a sodium urate-induced synovitis model
muscle mass revealed a significant reduction of atrophy,
in dogs. Am J Vet Res 1997;58:626–631.
suggesting a myotropic effect (data not shown).
r SC, Johnston SA, Schwarz PD, DeCamp CE, Claxton
The beneficial effects of QEVA on arthritic dogs were
f icacy of etodolac for the treatment of osteoarthritis of the
hip joints in dogs. J Am Vet Med Assoc 1999;214:206–210.
objectively and subjectively demonstrated in this study.
18. Dupuis J, Harari J, Papageorges M, Gallina AM, Ratzlaff M.
Based on the improvements observed here, consideration
Evaluation of fibular head transposition for repair of experimental
should be given to a powder of quality elk velvet antler
cranial cruciate ligament injury in dogs. Vet Surg 1994;23:1–12.
in the treatment of canine OA. Further fundamental
19. Dray A. Inflammatory mediators of pain. Br J Anaesth 1995;75:
investigation in OA cartilage explants to evaluate the
capacity of QEVA to reduce or inhibit the degenerative
process would be interesting. Also, the long-term safety
21. Goldring MB. The role of cytokine as inflammatory mediators in
of administering QEVA needs to be investigated, as does
osteoarthritis: lessons from animal models. Connect Ti
the magnitude of improvement with a well defined and
frequently prescribed OA medication on dogs afflicted
22. Konttinen YT,
r M, et al. Peripheral and
spinal neural mechanisms in arthritis, with particular reference to
treatment of inflammation and pain. Arthritis Rheum 1994;37:965–982.
23. DeCamp CE. Kinetic and kinematic gait analysis and the
assessment of lameness in the dog. Vet Clin North Am Small Anim Pract 1997;27:825–840.
The authors thank Mr. Sébastien Martel for technical
24. Cotran RS, Kumar V,
V Collins T.
T Robbins Pathologic Basis of
Disease, 6th ed. Philadelphia: W
B Saunders, 1999:11
Can Vet J Volume 45, February 2004
25. Clarke ML, Harvey DG, Humphreys DJ. Veterinary Toxicology,
cervical cord and effect of Pantui extract, pantocrin. Nippon
2nd ed. London: Baillière Tindall, 1981:140–149.
Yakurigaku Zasshi 1972;68:489–493.
26. Gilman AG, Goodman LS, Rall TW, Murad F, eds. Goodman and
29. Bali JP, Cousse H, Neuzil E. Biochemical basis of the pharmaco-
Gilman's The Pharmacological Basis of Therapeutics. 7th ed. New
logic action of chondroitin sulfates on the osteoarticular system.
York: Macmillan Publisher, 1985:1293.
Semin Arthritis Rheum 2001;31:58–68.
27. Takikawa K, Kokubu N, Tahara N, Dohi M. Experimental whiplash
30. Di Pasquale MG. Stimulants and adaptogens. Part 2. Drugs Sports
injury. 2. Evaluation of Pantui extract, pantocrine. Nippon
Yakurigaku Zasshi 1972;68:473–488.
28. Takikawa K, Kokubu N, Kajihara M, Doi M, Tahara N.
Experimental whiplash injury. 3. Changes in enzyme activities of
Appendix 1. Owner's assessment
Appendix 2. Surgeon's assessment
Daily life activities
· Walking approximately 15 minutes· Gait after 15 minutes of walking
· Running approximately 10 minutes
1 — Perceivable algetic gait
· Gait after 10 minutes of running
2 — Evident algetic gait
· Climbing stairs· Going down stairs
· Getting up after a long rest
1 — Abnormal (perceivable relief)
2 — Abnormal (obvious relief)
· Climbing in the car, over objects
0 — No limit of motion1 — Reduction of 10° to 20° of motion
2 — Reduction of 20° to 50° of motion
0 — No difficulty in performing this activity
3 — Reduction of more than 50° of motion
1 — Slight and occasional difficulty in performing this activity2 — Slight and constant difficulty in performing this activity
3 — Evident difficulty in performing this activity
1 — Perceptible muscular atrophy
4 — Can no longer execute this activity
2 — Evident muscular atrophy
Did you notice an increasing vitality in your dog? YES/ NO
Please report side effects related to treatment
1 — Slight (complete movement with
Score for each activities were added to generate a score for activity
2 — Moderate (incomplete movement with reluctance)3 — Severe (no movement allowed)
100 mm Severe algetic gait
aMuscular mass atrophy was assessed by palpation.
bOn a 100-mm line, the surgeon identified his own appreciation of the algetic gait, the resulting numeral length (score) was further analyzed.
Score for walking gait, trotting gait, posture, mobility, muscular atrophy, and joint pain were added to generate a score for clinical signs.
Appendix 3. Scoring system for radiographic evidence of osteoarthrosis
0 — Osteophytes and sclerosis absent.
1 — Acetabular remodeling, Morgan line, slight neck remodeling and slight femoral head sclerosis.
2 — Acetabular remodeling and osteophytosis, neck remodeling, enthesiophytosis, and femoral head sclerosis.
3 — Advanced acetabular and neck remodeling, severe osteophytosis and advanced femoral head sclerosis.
0 — Osteophytes absent.
1 — Osteophytes present on patella and proximal aspect of femoral trochlear groove.
2 — Osteophytes present on patella, femoral trochlear groove, medial and lateral femoral condyles, and tibial plateau.
3 — Severe osteophytes on patella, femoral trochlear groove, medial and lateral femoral condyles, and tibial plateau: subchondral sclerosis of femoral condyles and tibial plateau.
0 — Osteophytes absent.
1 — Osteophytes 2 mm on the anconeal process of ulna.
3 — Osteophytes 2 to 5 mm on the anconeal process of ulna, osteophytes on the head of radius 2 mm, and on the
humeral crest 2 mm.
Tarsus and shoulder
0 — Osteophytes absent1 — Osteophytes 2 mm2 — Osteophytes 2 to 5 mm3 — Osteophytes 5 mm
Can Vet J Volume 45, February 2004
Cell Physiol Biochem 2015;37:651-665 DOI: 10.1159/000430384 © 2015 S. Karger AG, Basel Published online: September 08, 2015 Spaas et al.: Chondr ogenic Priming Enhances MSC Adhesion ed: August 04, 2015 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to
Dambuza et al. Malar J (2015) 14:505 Open Access Antiplasmodial activity, in vivo pharmacokinetics and anti-malarial efficacy evaluation of hydroxypyridinone hybrids in a mouse modelNtokozo S. Dambuza1*, Peter Smith1, Alicia Evans1, Jennifer Norman1, Dale Taylor1, Andrew Andayi2, Timothy Egan2, Kelly Chibale2 and Lubbe Wiesner1 Abstract Background: During the erythrocytic stage in humans, malaria parasites digest haemoglobin of the host cell, and the toxic haem moiety crystallizes into haemozoin. Chloroquine acts by forming toxic complexes with haem mol-ecules and interfering with their crystallization. In chloroquine-resistant strains, the drug is excluded from the site of action, which causes the parasites to accumulate less chloroquine in their acid food vacuoles than chloroquine-sen-sitive parasites. 3-Hydroxylpyridin-4-ones are known to chelate iron; hydroxypyridone-chloroquine (HPO-CQ) hybrids were synthesized in order to determine whether they can inhibit parasites proliferation in the parasitic digestive vacuole by withholding iron from plasmodial parasite metabolic pathway.Methods: Two HPO-CQ hybrids were tested against Plasmodium falciparum chloroquine-sensitive (D10 and 3D7) and -resistant strains (Dd2 and K1). The pharmacokinetic properties of active compounds were determined using a mouse model and blood samples were collected at different time intervals and analysed using LC–MS/MS. For in vivo efficacy the mice were infected with Plasmodium berghei in a 4-day Peters' test. The parasitaemia was determined from day 3 and the course of the infection was followed by microscopic examination of stained blood films every 2–3 days until a rise in parasitaemia was observed in all test subjects.Results: IC50 values of the two compounds for sensitive and resistant strains were 0.064 and 0.047 µM (compound